Close Menu

Biodesix

The diagnostic firm has agreed with Streck to incorporate its blood collection tubes into sample collection protocols for its genomic lung cancer tests.

The firms will use Biodesix's biomarker discovery platform to analyze the proteome of pancreatic cancer patients treated with Immodulon's immunotherapy IMM-101.

Under the agreement, Biodesix will use the Thermo Fisher Ion Torrent Oncomine Pan-Cancer Cell-Free Assay to generate data to apply for FDA premarket approval.

Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.

The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.

The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.

The firm also increased the size of its Series G preferred shares offering and will use the funds to develop tests for guiding the use of cancer immunotherapy.

Biodesix will work with university researchers on an assay to help identify non-small cell lung cancer patients likely to respond to certain immunotherapies.

While the company has historically marketed the test's ability to predict patient drug response, it has more recently focused on its prognostic power.

Pages

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.